Dianne K. Bryce
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Chemical Synthesis and Analysis, Pharmacological Receptor Mechanisms and Effects, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism(2012)253 cited
- → Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.(1993)222 cited
- → Activity and Distribution of Binding Sites in Brain of a Nonpeptide Substance P (NK 1 ) Receptor Antagonist(1991)218 cited
- → LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits(2020)126 cited
- → The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine as a novel, nonpeptide substance P antagonist(1992)107 cited
- → Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models(2009)74 cited
- → Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.(1996)74 cited
- → 5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists(1994)70 cited
- → Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574(2013)61 cited
- → Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin NK1 receptor(1992)43 cited